Oral presentation of posttransplantation lymphoproliferative disorders: An unusual manifestation

Transplantation

Volumn 61, Issue 3, 1996, Pages 435-440

  Oda, Dolphine ^a   Persson, G Rutger ^a   Haigh, W Geoffrey ^a   Sabath, Daniel E ^b   Penn, Israel ^c   Aziz, Salim ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; CYCLOSPORIN;

ADULT; ARTICLE; CASE REPORT; EPSTEIN BARR VIRUS; GINGIVA HYPERPLASIA; GINGIVECTOMY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOID HYPERPLASIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; BASE SEQUENCE; CYCLOSPORINE; DNA PRIMERS; DNA, VIRAL; GINGIVAL HYPERPLASIA; HEART TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RISK FACTORS;

EID: 0030046178     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602150-00021     Document Type: Article

References (52)

1. Craig FE, Gulley ML, Banks PM. Post-transplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265.
2. Kaye MP. The Registry of the International Society for Heart and Lung Transplantation: tenth official report - 1993. J Heart Lung Transplant 1993; 12: 541.
3. Olson L, Rodeheffer R. Management of patients after cardiac transplantation. Mayo Clin Proc 1992; 567: 775.
4. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporin on some gingival health parameters of renal transplant patients. J Clin Periodontol 1987; 14: 610
5. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25: 365.
6. First MR. Transplantation in the nineties. Transplantation 1992; 53: 1.
7. Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplant Proc 1986; 18 (suppl 1): 210.
8. Loughran TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84: 2164.
9. Dambaugh T, Beisel C, Hummel M, et al. Epstein Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci USA 1980; 77: 2999.
10. Feinberg AP, Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6.
11. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106.
12. Matas AJ, Hertel BF, Rosai J, Simmons RL, Najarian JS. Post-transplant malignant lymphoma: distinctive morphologic features related to its pathogenesis. Am J Med 1976; 61: 716.
13. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs; 32 kidneys, 2 pancreas and 2 livers. Lancet 1979; 2: 1033.
14. Reitz BA, Bieber CP, Pennock JL. Cyclosporin A and lymphoma in non-human primates. In: Calne RY, White DJG, eds. Proceedings of the international symposium on Cyclosporin A. New York: Elsevier/North Holland, 1982: 317.
15. Canioni D, MacKelvie P, Debure A, Nezelof C. Lymphadenopathy in renal transplant patients treated with immunosuppressive antibodies (OKT3 and anti-thymocyte globulin). Am J Surg Pathol 1989; 13: 87.
16. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461.
17. Hanto DW, Birkenbach M, Frizzera G, et al. Confirmation of the heterogeneity of post-transplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47: 458
18. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Terasaki P, ed. Clinical transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory, 1990: 53.
19. Berg LC, Copenhaver CM, Morrison VA, et al. B cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization. Hum Pathol 1992; 23: 159.
20. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
21. Schubach WH, Miller G, Thomas ED. Epstein-Barr virus genomes are restricted to secondary neoplastic cells following bone marrow transplantation. Blood 1985; 65: 535.
22. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080.
23. Swinnen LJ, Constanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
24. Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions associated with phenytoin therapy. Arch Dermatol 1985; 121: 1181.
25. King GN, Fullinfaw R, Higgins TJ, et al. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993; 20: 286.
26. McGaw WT, Porter H. Cyclosporine-induced gingival over-growth: an ultrastructural stereologic study. Oral Surg Oral Med Oral Pathol 1988; 65: 186.
27. Messing RO, Carpenter CL, Greenberg DA. Mechanism of calcium channel inhibition by phenytoin: comparison with classical calcium channel antagonists. J Pharmacol Exp Ther 1985; 235: 407.
28. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy: report of a case. Oral Surg Oral Med Oral Pathol 1986; 57: 620.
29. DeLorenzo RJ. Phenytoin: calcium- and calmodulin-dependent protein phosphorylation and neurotransmitter release. Adv Neurol 1980; 27: 399.
30. Antman EM, Stone PH, Muller JE, Braunswald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I. Basic and clinical electrophysiologic effects. Ann Intern Med 1980; 93: 875.
31. Colombani PM, Robb A, Hess AD. Cyclosporin A binding to calmodulin: a possible site of action on T-lymphocytes. Science 1985; 228: 337.
32. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234.
33. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520.
34. Yousem SA, Randhawa P, Locker J. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients. Hum Pathol 1989; 20: 361.
35. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451.
36. Joncas JH, Russo P, Brochu P, et al. Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiencies. J Clin Oncol 1990; 8: 378.
37. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 4253.
38. Castro CJ, Klimo P, Worth A. Multifocal aggressive lymphoma of the gastrointestinal tract in a renal transplant patient treated with cyclosporin A and prednisone. Cancer 1985; 55: 1665.
39. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation: clinical, pathological, and virological findings and implications for therapy. Ann Surg 1983; 198; 356.
40. Klein G, Purtilo D. Summary: Symposium on Epstein-Barr virus-induced lymphoproliferative diseases in immunodeficient patients. Cancer Res 1981; 41: 4302.
41. Murray JE, Wilson RE, Tilney NL. Five years' experience in renal transplantation with immuno-suppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968; 168: 416.
42. List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987; 5: 1673.
43. Golder DT, Drinnan AJ. Dental aspects of cardiac transplantation. Transplant Proc 1993; 25: 2377.
44. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
45. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322: 485.
46. Fischer A, Griscelli C, Friedrich W, et al. Bone marrow transplantation for immunodeficiencies osteopetrosis: European survey, 1968. Lancet 1986; 2: 1080.
47. United Network for Organ Sharing. OPTN and transplant recipient annual report. Scientific registry of UNOS. Richmond, VA: United Network for Organ Sharing, 1995.
48. Wysocki GP, Laupacis A, Ulan RA, Stiller CR. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin-A therapy. Oral Surg Oral Med Oral Pathol 1983; 55: 274.
49. Adams D, Davies G. Gingival hyperplasia associated with cyclosporin: a report of two cases. Br Dent J 1984; 157: 89.
50. Rateitschak-Pluss EM, Hefti A, Lortscher R, Thiel G. Initial observations that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 1983; 10: 273.
51. Daley TD, Wysocki GP, Day C. Clinical and pharmacological correlations in cyclosporin-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986; 62: 417.
52. McGaw WT, Lam S, Coates J. Cyclosporin-induced gingival over-growth: correlation with dental plaque scores, gingivitis scores, and cyclosporin level in serum and saliva. Oral Surg Oral Med Oral Pathol 1987; 64: 293.